Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 3
2010 9
2011 19
2012 70
2013 99
2014 137
2015 172
2016 191
2017 250
2018 257
2019 267
2020 414
2021 474
2022 457
2023 443
2024 163

Text availability

Article attribute

Article type

Publication date

Search Results

2,976 results

Results by year

Filters applied: . Clear all
Page 1
Ruxolitinib Alleviates Renal Interstitial Fibrosis in UUO Mice.
Bai Y, Wang W, Yin P, Gao J, Na L, Sun Y, Wang Z, Zhang Z, Zhao C. Bai Y, et al. Int J Biol Sci. 2020 Jan 1;16(2):194-203. doi: 10.7150/ijbs.39024. eCollection 2020. Int J Biol Sci. 2020. PMID: 31929748 Free PMC article.
Ruxolitinib was administered to UUO mice and TGF-beta1-treated cells. Kidneys from UUO mice with Ruxolitinib treatment displayed less tubular injuries compared with those without Ruxolitinib treatment. ...
Ruxolitinib was administered to UUO mice and TGF-beta1-treated cells. Kidneys from UUO mice with Ruxolitinib treatment display …
Management of myelofibrosis after ruxolitinib failure.
Harrison CN, Schaap N, Mesa RA. Harrison CN, et al. Ann Hematol. 2020 Jun;99(6):1177-1191. doi: 10.1007/s00277-020-04002-9. Epub 2020 Mar 20. Ann Hematol. 2020. PMID: 32198525 Free PMC article. Review.
Ruxolitinib reduces splenomegaly to some degree in almost all treated patients; however, many patients cannot tolerate ruxolitinib due to dose-dependent drug-related cytopenias, and even patients with a good initial response often develop resistance to ruxolitini …
Ruxolitinib reduces splenomegaly to some degree in almost all treated patients; however, many patients cannot tolerate ruxolitinib …
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis.
Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J. Mesa RA, et al. J Clin Oncol. 2017 Dec 1;35(34):3844-3850. doi: 10.1200/JCO.2017.73.4418. Epub 2017 Sep 20. J Clin Oncol. 2017. PMID: 28930494 Free PMC article. Clinical Trial.
Results A 35% reduction in spleen volume at week 24 was achieved by a similar proportion of patients in both treatment arms: 26.5% of the momelotinib group and 29% of the ruxolitinib group (noninferior; P = .011). A 50% reduction in the total symptom score was observed in …
Results A 35% reduction in spleen volume at week 24 was achieved by a similar proportion of patients in both treatment arms: 26.5% of the mo …
Utilization of Topical Ruxolitinib in Dermatology: A Review.
Kashetsky N, Turchin I. Kashetsky N, et al. Skin Therapy Lett. 2023 May;28(3):8-13. Skin Therapy Lett. 2023. PMID: 37339609 Free article. Review.
As systemic administration of Janus kinase-inhibitors is associated with safety concerns, local alternatives, such as topical ruxolitinib, have been developed. This review summarizes utilization of topical ruxolitinib in dermatology. ...Results show improvement with …
As systemic administration of Janus kinase-inhibitors is associated with safety concerns, local alternatives, such as topical ruxolitinib …
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. Verstovsek S, et al. N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557. N Engl J Med. 2012. PMID: 22375971 Free PMC article. Clinical Trial.
BACKGROUND: Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis. ...RESULTS: The primary end point was reached in 41.9% of patients in the ruxolitinib group as compared with 0.7% in the placebo group …
BACKGROUND: Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis. . …
Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.
Keenan C, Nichols KE, Albeituni S. Keenan C, et al. Front Immunol. 2021 Feb 16;12:614704. doi: 10.3389/fimmu.2021.614704. eCollection 2021. Front Immunol. 2021. PMID: 33664745 Free PMC article. Review.
To improve upon these results, studies have focused on the use of novel cytokine-directed therapies to dampen inflammation in HLH. Among the agents being tested is ruxolitinib, a potent inhibitor of the Janus Kinase (JAK) and Signal Transducer and Activation of Transcripti …
To improve upon these results, studies have focused on the use of novel cytokine-directed therapies to dampen inflammation in HLH. Among the …
Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review.
Appeldoorn TYJ, Munnink THO, Morsink LM, Hooge MNL, Touw DJ. Appeldoorn TYJ, et al. Clin Pharmacokinet. 2023 Apr;62(4):559-571. doi: 10.1007/s40262-023-01225-7. Epub 2023 Mar 31. Clin Pharmacokinet. 2023. PMID: 37000342 Free PMC article.
RESULTS: Ruxolitinib is well absorbed, has 95% bio-availability, and is bound to albumin for 97%. Ruxolitinib pharmacokinetics can be described with a two-compartment model and linear elimination. ...
RESULTS: Ruxolitinib is well absorbed, has 95% bio-availability, and is bound to albumin for 97%. Ruxolitinib pharmacokinetics …
Ruxolitinib.
Becker H, Engelhardt M, von Bubnoff N, Wäsch R. Becker H, et al. Recent Results Cancer Res. 2014;201:249-57. doi: 10.1007/978-3-642-54490-3_16. Recent Results Cancer Res. 2014. PMID: 24756798 Review.
Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of JAK1 and JAK2. ...Ruxolitinib treatment results in a meaningful reduction in spleen size and symptom burden in the majority of myelofibrosis patients, and it may also ha …
Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral inhibitor of JAK1 and JAK2. ...Ruxolitinib …
Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
Pemmaraju N, Bose P, Rampal R, Gerds AT, Fleischman A, Verstovsek S. Pemmaraju N, et al. Leuk Lymphoma. 2023 Jun;64(6):1063-1081. doi: 10.1080/10428194.2023.2196593. Epub 2023 Apr 20. Leuk Lymphoma. 2023. PMID: 37081809 Review.
As a first-in-class targeted treatment, ruxolitinib approval transformed the MF treatment approach and remains standard of care. ...Lastly, future directions for MF treatment are discussed, including ruxolitinib-based combination therapies....
As a first-in-class targeted treatment, ruxolitinib approval transformed the MF treatment approach and remains standard of care. ...L …
Ruxolitinib for the treatment of graft-versus-host disease.
Ali H, Salhotra A, Modi B, Nakamura R. Ali H, et al. Expert Rev Clin Immunol. 2020 Apr;16(4):347-359. doi: 10.1080/1744666X.2020.1740592. Epub 2020 Apr 1. Expert Rev Clin Immunol. 2020. PMID: 32153201 Review.
Introduction: Ruxolitinib is an oral selective JAK1/JAK2 inhibitor, initially approved by the FDA for the treatment of intermediate-2 or high-risk myelofibrosis and patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea.Areas c …
Introduction: Ruxolitinib is an oral selective JAK1/JAK2 inhibitor, initially approved by the FDA for the treatment of intermediate-2 …
2,976 results

Searches related to "ruxolitinib"